2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

StemRIM Inc.

Company Presentations

Thursday, July 23 Company Presentations 3–Japan

StemRIM Inc.

Company Info

Name /StemRIM Inc.

Address /Saito Bio-Incubator 3F, 7-7-15 Saito-Asagi, Ibaraki City, Osaka, 567-0085 Japan

Website /stemrim.com/english/

Presenter

Name /Masatsune Okajima

Title /President and COO

Email /okajima@stemrim.com

Telephone /(Work) +81-72-648-7152

Fax /+81-72-648-7153

Mobile /+8190-5996-6170

Company Type

Biotechnology

About the Company

StemRIM is a drug discovery research and development-oriented biotech company originating from Osaka University Japan. The company was established in 2006 with the aim of developing a mesenchymal stem cell recruitment factor as a pharmaceutical product, which was identified by Professor Tamai and his colleagues at the Graduate School of Medicine, Osaka University. Since then, through joint research with Osaka University, StemRIM has been consistently worked on the development of “Regeneration-Inducing Medicine”, which is a medicine promoting functional tissue regeneration and enabling the treatment of intractable diseases.

The company has been listed on the Tokyo Stock Exchange Mothers from Aug. 2019.

Brief Description of main products or services

The company’s main product, “Regeneration-inducing Medicine” is a next-generation and an innovative new class of regenerative medicine that induces functional regeneration of patient’s tissues and organs damaged due to injury or illness by maximizing the human body's innate ability of tissue repairing, only through drug administration without using living cells and tissues. Inherently, organisms are equipped with the ability to repair their damaged tissues. This ability is carried by the tissue stem cells existing in organisms. Regeneration-inducing Medicine promotes tissue regeneration by increasing the supply of those tissue stem cells, by mobilizing bone marrow mesenchymal stem cells into the peripheral blood stream, resulting in accumulating them in the damaged tissue for tissue repairing.

The efficacy of the leading product, a peptide-based drug, Redasemtide, in patients with dystrophic epidermolysis bullosa was confirmed by the investigator-initiated Phase II clinical study conducted at Osaka University and other institutions, and now the licensee pharmaceutical company of the product, Shionogi & Co., Ltd. is preparing for NDA submission. Shionogi is also conducting Phase II clinical study for acute ischemic stroke. Furthermore, StemRIM and Shionogi are now preparing other clinical studies for this product in three new indications (chronic liver disease, knee osteoarthritis, and cardiomyopathy).

Contact Person

Name /Masatsune Okajima

Email /okajima@stemrim.com

Phone /(Work) +81-72-648-7152